InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (6 ops.)
Insider track record
OtherDisclosed buys
3
Disclosed sells
6
T+90 hit rate
0%
T+90 mean return
-37.3%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Medicxi Ventures Management (Jersey) Ltd. Director active across 2 companies, notably Centessa Pharmaceuticals plc. Cumulatively, 12 reports have been recorded. Split: 3 buys · 6 sells. Total volume traded: €867k. Activity tracked since 26 November 2021. The latest transaction was filed on 21 March 2022 (J). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Medicxi Ventures Management (Jersey) Ltd
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations12 total
4,398,519 sharesOrdinary SharesSEC:0001193125-26-281115:0
55,677 sharesOrdinary SharesSEC:0001193125-26-281115:1
3,936,970 sharesOrdinary SharesSEC:0001193125-26-281115:2
93,526 sharesOrdinary SharesSEC:0001193125-26-281115:3
11,197,303 sharesOrdinary SharesSEC:0001193125-26-281115:4
281,162 sharesOrdinary SharesSEC:0001193125-26-281115:5
1,794,211 shares0Ordinary SharesSEC:0000899243-22-011938:0
33,530 shares@ US$12.8243.8% of flowOrdinary SharesSEC:0000899243-21-046968:0
Canonical exit: 2 Mar 2022 (T+90)
35,992 shares@ US$11.6242.7% of flowOrdinary SharesSEC:0000899243-21-046591:0
Canonical exit: 28 Feb 2022 (T+90)
11,543 shares@ US$11.335313.5% of flowOrdinary SharesSEC:0000899243-21-046316:0
Canonical exit: 24 Feb 2022 (T+90)
2,275,827 sharesCommon StockSEC:0000899243-21-043033:0
1,886,990 sharesOrdinary SharesSEC:0000899243-21-022048:0
12 of 12 declarations
About Medicxi Ventures Management (Jersey) Ltd
Medicxi Ventures Management (Jersey) Ltd is a declarant with 12 filings in total. In the recent filings we hold, the activity runs from 2021-06-04 to 2026-06-24, with EUR 866798 of buys and EUR 0 of sells. The entity is linked to Centessa Pharmaceuticals plc as a 10% Owner and to Aura Biosciences, Inc.
